A Mixed Methods Investigation of Equine-assisted Occupational Therapy for Children With Autism
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03493347 |
|
Recruitment Status :
Completed
First Posted : April 10, 2018
Last Update Posted : April 12, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Autism Spectrum Disorder | Behavioral: Equine-assisted Occupational Therapy | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 8 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | multiple baseline single case experimental design |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Mixed Methods Investigation of Equine-assisted Occupational Therapy for Children With Autism |
| Actual Study Start Date : | July 24, 2017 |
| Actual Primary Completion Date : | December 18, 2017 |
| Actual Study Completion Date : | December 31, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Equine-assisted Occupational Therapy
All children will receive the Equine-assisted Occupational Therapy (EAOT) intervention, which includes occupational therapy administered in an equine environment. Common intervention activities include grooming, tacking, mounting, and riding the horse.
|
Behavioral: Equine-assisted Occupational Therapy
Occupational therapy provided in an equine environment that includes activities such as groundwork, grooming, tacking, mounting, and riding horses |
- Change in Visual Analog Scale (VAS) ratings of individualized occupational performance goals [ Time Frame: daily, during baseline and intervention phases (up to 119 days) ]Parents rate their child's performance on an individualized goal using a sliding scale. The minimum score of 0, indicated on the left of the scale, denotes poor performance, while the maximum score 100, on the right of the scale, denotes excellent performance.
- Change in Irritability [ Time Frame: Weekly during baseline and intervention phases, up to 18 weeks. Also during 3-month follow-up. ]Irritability subscale of the Aberrant Behavior Checklist- Community (ABC-C). The minimum score of 0 denotes an absence of irritable behaviors, while to maximum score of 45 denotes frequent and severe irritable behaviors.
- Change in Hyperactivity [ Time Frame: Weekly during baseline and intervention phases, up to 18 weeks. Also at 3-month follow up. ]Hyperactivity subscale of the Aberrant Behavior Checklist- Community (ABC-C). The minimum score of 0 denotes an absence of hyperactive behaviors, while the maximum score of 48 denotes frequent and severe hyperactive behaviors.
- Change in Social Functioning [ Time Frame: 4 Time Points: initial, after 5-7 weeks of no-treatment baseline, after 10 weeks of intervention, and after a 3-month follow-up period. ]Parent ratings on the Social Responsiveness Scale, Second Edition. The scale ranges from 0 - 195, where higher scores indicate more social impairment.
- Change in Canadian Occupational Performance Measure [ Time Frame: 4 Time Points: initial, after 5-7 weeks of no-treatment baseline, after 10 weeks of intervention, and after a 3-month follow-up period. ]Parent ratings of performance and satisfaction with their child's progress towards individualized goals. Administered in a semi-structured interview format. Ratings range from 0 - 10, where larger scores indicate better performance or higher levels of satisfaction.
- Parent Perceptions of Child's Response to Treatment [ Time Frame: Two time points: 1-2 months after the intervention is complete (January-February 2018) and 5 months after intervention is complete (May 2018) ]Semi-structured interviews with parents to obtain their perceptions of the therapy
- Therapist Clinical Reasoning [ Time Frame: Weekly basis for 10 weeks throughout intervention phase. ]Semi-structured interviews with therapists to understand their clinical reasoning guiding how the intervention was designed and delivered
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 5 Years to 14 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- aged 5-14
- have an ASD diagnosis by a community provider
- score ≥15 on the Social Communication Questionnaire
- score ≥11 on the Aberrant Behavior Checklist-Community
- meets clinical cut-offs for ASD on the Autism Diagnostic Observation Schedule, Second Edition
- score ≥55 on the Leiter International Performance Scale, Third Edition
- can tolerate a helmet
- can participate in 10-minutes of riding while following safety rules
- meets physical, mental, and emotional standards set forth by the Professional Association of Therapeutic Horsemanship, International
Exclusion Criteria:
- behavioral issues that could interfere with safety
- 2 hours or more of previous experience with equine-assisted interventions in the last 6 months
- weight exceeding 200 pounds
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03493347
| United States, Colorado | |
| Hearts and Horses Therapeutic Riding Center | |
| Loveland, Colorado, United States, 80537 | |
| Principal Investigator: | Wendy Wood, Ph.D. | Colorado State University |
| Responsible Party: | Wendy Wood, Director of Research, Temple Grandin Equine Center, Colorado State University |
| ClinicalTrials.gov Identifier: | NCT03493347 |
| Other Study ID Numbers: |
17-7112H |
| First Posted: | April 10, 2018 Key Record Dates |
| Last Update Posted: | April 12, 2019 |
| Last Verified: | April 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Autistic Disorder Autism Spectrum Disorder Child Development Disorders, Pervasive Neurodevelopmental Disorders Mental Disorders |

